The purpose of this progression collaboration agreement is for Arzeda to design and expand new enzymes for Amyris with unique features, which Amyris will incorporate into her fermentation procedure to facilitate the production of high-priced target ingredients. The investment of the project is discovered in milestones, with Arzeda receiving an additional payment discovered for immediate good fortune, as well as a percentage of the price in the marketing of the product. Enzymes designed and developed through Arzeda for this assignment are not discovered in nature and therefore constitute the strength of the computational platform to build enzymes. with unique features without an herbal starting point. Amyris and Arzeda hope to have fermentation strains containing enzymes designed through Arzeda evolved in 2021.
“We are excited to work with Amyris again on the advent of new products by combining protein design and strain engineering,” said Alexandre Zanghellini, CEO of Arzeda. “Amyris is a pioneer in artificial biology, and our previous collaboration has given us super respect for her technical competence and professionalism. We have witnessed how Amyris’ generation platform can drastically drive the progression of products incorporating Arzeda’s author’s enzymes and proteins, and we look to this new trade association. “